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ABSTRACT
Background. Cancer registries have been set up world-
wide to provide information for cancer health planning.
There are known variations in breast cancer incidence and
mortality worldwide. However, breast cancer incidence,
pathological characteristics, and survival data is still under-
reported in Asian countries. This is the first comprehensive
population-based breast cancer study performed using
population database of the Hong Kong Cancer Registry.
Methods. A retrospective review of medical records of
8,961 subjects who were diagnosed with breast cancer
between January 1, 1997 to December 31, 2001 and followed
up to December 31, 2007. Descriptive statistics were
employed to analyze the epidemiological and clinical data.
Estimates of overall, disease-free, and cancer-specific sur-
vival at 5 years were estimated by the Kaplan–Meier method
and stage-specific relative survival rates were calculated.
Results. A total of 7,630 breast cancer patients’ medical
records and dataset were available during this period, and
7,449 subjects were eligible for the final analysis. Median
follow-up was 84 months. A total of 47.4% were diagnosed
with breast cancer at age 49 years and younger; 22.2%,
46.9%, 10.8%, and 4.1% presented at stages I, II, III, and
IV, respectively. A total of 53.5% had ER-positive cancer,
and 20.3% had HER2-positive cancers; 13.4% had triple-
negative cancers. The relative, cancer-specific, and disease-
free survival rates at 5 years were 84%, 85.2%, and 81.2%,
respectively.
Discussion. We performed the first comprehensive popu-
lation-based breast cancer epidemiology study in Southern
China using the Hong Kong Cancer Registry database. This
provides a baseline study cohort for comparative studies
with other Asian countries and Chinese who have migrated
to the West.
Incidence rates of breast cancer have been increasing
throughout the world.1 Breast cancer ranked the fifth, after
lung, stomach, liver, and colon cancers, causing 460,000
deaths in 2008.2 Approximately 200,000 new cases are
diagnosed with invasive breast cancer every year in the
United States.3 Among women in the United States, breast
cancer is the most common cancer and the second leading
cause of cancer-related death in the United States.4 In Asia,
the highest incidence (53.7 per 100,000) of breast cancers
is in Manila, Philippines.5 An early study by Lin et al.
investigated the epidemiology characteristics of breast
cancer in a defined region of Northern Taiwan.6 The crude
average annual incidence rate between 1964–1967 was
6.11 per 100,000 female population.6 Age-specific inci-
dence rates showed a pattern similar in Japan and in the
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Chinese population of Singapore. The rates plateau in the
middle-age and then declined in the older age groups.6
Mortality rates, however, consistently increased with age
throughout the life span.6 A later study by Huang and
colleagues demonstrated that the incidence of breast cancer
ranked first in Taiwan, China, Singapore, Japan, and India
in Asia.7 A study of 14,230 women age 25 years and older
who died from breast cancer between 1995 and 2006 in
Taiwan showed that the mortality rates increased dramat-
ically with increasing age, and significant differences were
observed for all age groups in the annual mortality rates
from breast cancer.8 Shin et al. recently reported similar
trends in breast cancer mortality in five Asian populations.9
Breast cancer mortality tended to decrease slightly in Hong
Kong and Singapore after year 1990 except for women
aged older than 70 years, in contrast to increased breast
cancer death rates throughout the entire study period in
Taiwan and Japan.9 Breast cancer death rates were almost
the same in Taiwan and Japan before the 1990s, whereas it
increased more steeply in Taiwan and then began rising
more rapidly in Japan than in Taiwan after 1996.9,10 The
most rapid increases in breast cancer mortality, and for all
age groups, were in Korea.9 In Hong Kong, breast cancer
overtook lung cancer to become the highest cancer inci-
dence rate in women in 1994.11 A woman’s risk of
developing breast cancer before the age of 75 years is 1 per
21 and is increasing.12 The age-standardized incidence
rates of breast cancer had been increasing from 32.5 per
100,000 in year 1983 to 35.0 per 100,000 in 2004 and
further increased to 45.9 per 100,000 in 2008.11,13,14
The difference in incidence rates and trends between
Caucasians and Asian populations demonstrated great
interest in further research in a still underexplored area in
understanding the epidemiology of breast cancer in Asians.
These ethnic differences are not only seen between Cau-
casians and Asians but also other ethnic groups. Hispanic
women had a 1.5-fold increased risk of breast cancer-
related death, relative to non-Hispanic women (95% con-
fidence interval (CI), 1.2–1.8).15 Unlike the Caucasian
population in the United States where the incidence rate of
breast cancer peaked between age 45 and 55 years, the
incidence rate for Hong Kong Chinese women peaked at
age 40 years, i.e., earlier than that in the Caucasian popu-
lation.16 Studies also demonstrated that the incidence rates
of breast cancer in Caucasians continued to increase after
the peak incidence age and reached menopause, whereas a
plateau after the age of peak incidence was observed in
Hong Kong females.17–19 Our previous study on breast
cancer in Chinese female patients with operable breast
cancer who received primary treatment found that the age
distribution between Hong Kong Chinese and Chinese and
Caucasian women residing in the United States were sig-
nificantly different.20 Age-adjusted incidence found that a
higher proportion of younger women presented with breast
cancer compared with SEER data in the United States
(12.1% for the period of 2000–2004 in Hong Kong vs. 8%
in the United States).13,14,20,21 Incidence rates from 44
cancer registries in 15 countries in Asia published in
‘‘Cancer Incidence in Five Continents Volume IX’’ also
showed great variations across Asia, with approximately
threefold differences in both males and females.22 All of
these findings showed great potentials of more in-depth
investigations on the epidemiology of breast cancer in
Southern Chinese.
To our knowledge, this is the first population-based
study for female Chinese in Hong Kong, Southern China.
The data would contribute much to understand the epide-
miology of female breast cancer in Southern Chinese, and
the results also could be compared with other populations
in Asia and Western countries.
METHODS
This is a retrospective study based on the data collected
through the Hong Kong Cancer Registry (HKCaR) with
contribution from the prospectively collected database
from the University of Hong Kong. HKCaR is a popula-
tion-based registry established in 1963 which covers the
entire Hong Kong population.12 The study has been
approved by the institute review committee in Hong Kong.
HKCaR also is a member of the International Association
of Cancer Registries (IACR), providing international
standard on data management and accuracy. HKCaR
compiles reports on cancer statistics using demographic
date, information on the anatomical site, and histopathol-
ogy from different institutions in Hong Kong. HKCaR
provides a framework for comparative geographical, epi-
demiological, and clinical research. Apart from patient
demographic characteristics, such as age at diagnosis, the
following data were collected or verified: date of diagnosis
(accurate to the month), tumor side (left or right), last date
seen, and status of disease when last seen; if death, the
cause of death; if relapse, date of relapse, clinical man-
agement, such as mode of presentation, diagnosis, surgical
treatment, and adjuvant therapy given; prognostic markers,
such as tumor size, tumor type, tumor grade, lymph node
status, stage at diagnosis, estrogen (ER), and progesterone
receptors (PR) status, and HER2 status. Histological tumor
grading was performed using the Bloom and Richardson
classification system.23 Tumor staging was performed
according to the American Joint Committee on Cancer
criteria 6th edition (AJCC).24,25
Our database covered all 8,961 women who were
diagnosed with breast cancer between January 1, 1997 and
December 31, 2001. A total of 7,630 (85.1%) medical
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records of women who were diagnosed with breast cancer
for the period were successfully retrieved and reviewed
both from the existing database of the University of Hong
Kong and HKCaR. These records were matched with the
HKCaR, Hong Kong Death Register, and databases from
Hong Kong Hospital Authority’s data warehouse. A total
of 181 cases were excluded from the survival analysis for
the following reasons: diagnosis based on death certificate
only; unknown age at diagnosis; aged C100 years; and
completely lost to follow-up. The final analysis was based
on the cohort of the remaining 7,449 patients followed up
until December 31, 2007.
Statistical Analysis
Descriptive statistics were employed to describe the
epidemiological, clinical, and diagnostic data. Mean and
standard deviation (SD), and median if suitable, were used
to express the numeric data. Overall survival (OS), cancer-
specific survival (CSS), and disease-free survival (DFS)
were calculated by using the life-table method. OS was
defined as the time from diagnosis to death from any cause.
CSS was defined as the time from diagnosis to death due to
breast cancer. DFS among patients with stage I to III dis-
ease was defined as the time from diagnosis to the first
event of recurrent disease or breast cancer death. These
calculations were performed with the Statistical Package
for the Social Sciences (SPSS) version 16.0 (IBM Corp,
Somers, NY). Relative survival (RS) was computed by the
ratio of the observed survival in the study population to the
expected survival in the general population of the same age
and sex. Expected survival rates were derived from life
tables of the general Hong Kong population using the
Hakulinen method.26,27 RS is a useful alternative measure
that assesses the proportion of excess deaths that occur
compared with the general population. All RS ratios were
estimated using the SURV3 software.28
RESULTS
A total of 7,449 invasive breast cancer patients between
1997 and 2001 were eligible for this study. Patient char-
acteristics were tabulated in Table 1. The mean and median
of ages at diagnosis were 54 and 50 years, respectively.
The incidence of breast cancer peaked at age 45 years,
plateaued after age 55 years, and increased after age
70 years (Fig. 1). There is a slightly higher chance for the
patients to have breast cancer in the left breast than right
(50.4% vs. 47.2%).
Of those with invasive cancers, 47.4% of our cohort was
diagnosed with breast cancer at age 49 years or younger;
81.8% had invasive ductal carcinomas and 3.5% had
invasive lobular cancers. Of those known, 15.7%, 43.5%,
and 40.8% had grades I, II, or III cancer, respectively,
26.4%, 55.8%, 12.9%, and 4.9% had stages I, II, III, and IV
cancers at diagnosis, respectively, and 53.5%, 41.4%, and
20.3% patients were diagnosed with ER-positive, PR-
positive, and HER2-positive cancers, respectively. Of those
known with completed tumor expression, 13.4% had triple-
TABLE 1 Baseline characteristics of 7,449 patients with invasive
breast cancer
Characteristics N %
Age (years)
\50 3530 47.4
[50 3919 52.6
Laterality
Left 3756 50.4
Right 3515 47.2
Bilateral 118 1.6
Unknown 60 0.8
Histological type
Ductal 6093 81.8
Lobular 262 3.5
Other 1094 14.7
Histological grade
I 856 11.5
II 2368 31.8
III 2218 29.8
Unknown 2007 26.9
Stage
I 1653 22.2
II 3491 46.9
III 807 10.8
IV 305 4.1
Unknown 1193 16
ER
Positive 3984 53.5
Negative 2034 27.3
Unknown 1431 19.2
PR
Positive 3087 41.4
Negative 2778 37.3
Unknown 1584 21.3
HER2
Positive 1512 20.3
Negative 1968 26.4
Unknown 3969 53.3
Chemotherapy
Yes 3607 48.4
No 2858 38.4
Unknown 984 13.2
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negative cancers; 55.8% had chemotherapy, 60.2% had
radiation therapy, and 85.7% of those who had ER-positive
cancer received tamoxifen. At the end of the study, 1,872
(25.1%) of the patients had either relapsed or have died of
breast cancer. The median time to relapse or breast cancer
death was 35.7 months and mean time was 29 months. Of
patients who had invasive breast cancer, 27.5% had died by
the end of study, of whom 65.2% died from breast cancer,
9.6% died from cancers other than breast cancer, and
25.1% died from causes other than cancer. The RS, CSS,
and DFS at 5 years were 84%, 85.2%, and 81.2%,
respectively (Fig. 2). The stage-specific RS at 5 years were
97.5%, 87.8%, 66.2%, and 19.3% for stages I, II, III, and
IV, respectively (Fig. 3).
DISCUSSION
Cancer registries have been set up worldwide to provide
information on cancers, such as breast cancer. This
information has been published in many western countries,
but reports from Asia are generally from individual centers
or combinations of a few registries or centers within a
country rather than a complete population-based study. A
study in Mainland China also found that the consistency in
data collection between local registries may be variable.29
We therefore performed a first comprehensive population-
based breast cancer epidemiology and survival study in
women in Hong Kong, Southern China, using the Hong
Kong Cancer Registry database. A previous study per-
formed by The Hong Kong Hereditary Breast Cancer
Registry found that 84% of the women with breast cancer
who reside in Hong Kong originated from Guangdong
province in Southern Mainland China.30 Although nearly
70% of them were born in Hong Kong, more than 70% of
these patients’ parents originated and resided in Mainland
China. Hong Kong is a unique place to study breast cancer
trend in China because it was ruled by the British for
99 years and therefore is more westernized compared with
the rest of China. Indeed, the incidence of breast cancer in
Hong Kong, although lower than western countries, are
among the highest in Asia, on par with Singapore and
Japan, both of which are more developed and westernized
areas within Asia.31–33 The offspring of Asian women, in
particular Japanese, who have migrated to the United
States, have been found to have increased breast cancer
incidence compared with those residing in Japan.34 The
risk of breast cancer of Asians born in the west is increased
by sixfold compared with those born in the east, likely due
to the change of lifestyle, which can influence a number of
risk factors related to breast cancer, such as nutrition,
reproductive, and hormonal factors.35 The incidence of
breast cancer in Mainland China ranges from 10–60 per
100,000. This depends strongly on the location where the
FIG. 1 Age-specific incidence rates for invasive breast cancer in
Hong Kong, 1997–2001
FIG. 2 Relative survival (RS), cancer-specific survival (CSS), and
disease-free survival (DFS) of patients with invasive breast cancer in
Hong Kong
FIG. 3 Relative survival of patients with invasive breast cancer by
stage at diagnosis in Hong Kong
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incidence data has been obtained and is less in the rural
areas of China. The incidence however has rapidly
increased particularly in more developed cities, such as
Shanghai, during the past decade where lifestyle is now
similar to that of Hong Kong.36 With Hong Kong handed
over to the People’s Republic of China since 1997, under
the ruling of ‘‘one country, two systems,’’ Hong Kong has
remained independent. The access of mainland Chinese
migrants to Hong Kong, especially through marriages, has
increased during the past 5 years. This is likely to result in
a change of the disease pattern of breast cancer within
Hong Kong during the next decade with migrants of dif-
ferent Chinese ancestries having different socioeconomic
backgrounds and lifestyle. These may indirectly affect the
risk of breast cancer.37 Therefore, this study will be
important to serve as a baseline study of breast epidemi-
ology in the region and assist worldwide international
comparison studies where there is an increase influx of
Chinese migrants from mainland China.
Survival information is not always available in studies
performed by cancer registries worldwide. It has been
known that mortality and survival rates can vary between
countries. The role of population based cancer registries
had evolved not only to report the incidence and trends of
cancer but to include survival information, which has
become increasingly important for better evaluation and
planning of cancer control measures.38 The role of stage at
presentation and stage-specific survival emphasizes the
need for early diagnosis and treatment of cancer to achieve
a better outcome.39 The age-standardized relative survival
rate is the most commonly reported but is much underre-
ported in Asian countries. A study on survival rates of five
continents included information from Japan but none from
China,40 and there have been various studies on survival
information in Chinese but none population-based.41 More
detailed population-based survival information, including
stage-specific and cancer-specific survival, is even less well
reported.
Our study found a relative survival of 84%, which is
comparable to that of other western reports and 87% from
the SEER database during that same study period.42,43 The
comparable cancer-specific survival of 85.2% with relative
survival and the worsening survival associated with a later
stage of diagnosis of the disease emphasizes the impor-
tance of the need for earlier diagnosis. Of those patients
with known staging information, only 26.4% of our cohort
presented with stage I disease; the majority presented with
stage II or later disease. Although screening facilities are
available in Hong Kong, we do not have a population
screening program and patients have to attend screening on
a voluntary basis. This may, in addition, be limited by
financial constraints because insurance policy is still not
widely practiced, and there is no government subsidy for
screening. Only approximately 20% of women in Hong
Kong practice breast screening likely due to the afore-
mentioned constraints.11,44,45
Of those patients with known ER, PR, and HER2
receptor status, our cohort has a similar triple-negative rate
compared with western data (13.4% vs. 11.2%). However,
60% of patients did not have HER2 receptor status. This
was likely due to the specific time period of study, where
the use of targeted therapy, such as trastuzumab, was still
not widely available, and therefore the HER2 status was
not performed. Even when trastuzumab became available,
the use was limited. Similar to screening, there are only
limited subsidy support from the government and therefore
financial constraints would limit its use and also the per-
formance of testing for HER2 status. With the emergent of
more targeted therapy, the knowledge of the status of
hormonal receptors and HER2 receptors in our population,
which was previously underreported in Asia, would be
important for health care planning.
The strength of this study is the completeness and high
degree of accuracy of the data collection. The limitations of
the study are the lack of information on social background,
such as education and income level, and risk factors, such
as reproductive history, gynecological history, body
weight, hormonal intake, nutritional information, and
family history. The lack of details of screening practice and
treatment data also provided a limited picture on breast
cancer treatment and influence on the prognosis of the
disease. This study’s emphasis was on the reporting of the
various tumor biology and various survival rates in our
cohort, and hence, discussing risk factors, screening prac-
tice, and treatment information is beyond the scope of this
study and will be reported in a separate study. With the full
implementation of a population-wide computer medical
record system in 2000 in Hong Kong, it is likely that such
information would be easily accessible for data collection.
A retrospective study of a large-scale data collection on
such details on the present dataset is being implemented.
CONCLUSIONS
This study provides the first population-based analysis
on epidemiological, pathological characteristics, and sur-
vival, including stage-specific and cancer-specific survival
data for women with breast cancer in Hong Kong, Southern
China. As a baseline study, this would provide information
for further analysis on the association between risk factors
and breast incidence in our locality and treatment modal-
ities on the outcome of breast cancer. Further analysis with
longer follow-up periods and a larger cohort would enrich
the information for planning of screening, management,
and preventative strategies in the Asia region and may
3076 A. Kwong et al.
indirectly benefit worldwide health planning due to the
increase in Chinese migrants around the world.
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